Chronic Immune-Related Adverse Events Persist After Adjuvant Anti-PD-1 Therapy in Melanoma
Melanoma patients on adjuvant anti-PD-1 therapy can retain chronic immune-related adverse events long after treatment, shifting long-term toxicity follow-up toward dermatology clinics.